DCs can present antigens to CD8+ T cells, or secrete IL-12 to activate killer T cells, then result in clearing cancer cells, meanwhile, IFNγ secreted by activated killer T cells promote DCs maturation through a positive feedback regulation.[69] Currently, DCs are extensively studied in anti-cancer vaccine development.[70] The above proved the reliability that high-expression of the key gene RORC could suppress the COAD by recruiting DCs through Th17 cells in the low-risk group when environmental factors IL-1β were present. The gene discussed is CD8A; the disease is cancer.